ArticleGene therapy2008
Connective tissue growth factor linked to the E7 tumor antigen generates potent antitumor immune responses mediated by an antiapoptotic mechanism.
Article in Gene therapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 28 citations in OpenAlex.
- CTGF (CCN2): a multifaceted mediator in breast cancer progression and therapeutic targeting.Cancer metastasis reviews · 2025Review
- Enhanced HIV immune responses elicited by an apoptotic single-cycle SHIV lentivector DNA vaccine.Frontiers in cellular and infection microbiology · 2025Article
- Article
- Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases.Human gene therapy · 2018Article
- Irradiation Enhances Abscopal Anti-tumor Effects of Antigen-Specific Immunotherapy through Regulating Tumor Microenvironment.Molecular therapy : the journal of the American Society of Gene Therapy · 2018Article
- Mesothelin-specific cell-based vaccine generates antigen-specific immunity and potent antitumor effects by combining with IL-12 immunomodulator.Gene therapy · 2016Article
- Anti-CD40 antibody and toll-like receptor 3 ligand restore dendritic cell-mediated anti-tumor immunity suppressed by morphine.American journal of cancer research · 2016Article
- The role of CCN family genes in haematological malignancies.Journal of cell communication and signaling · 2015Article
- Fusion protein vaccines targeting two tumor antigens generate synergistic anti-tumor effects.PloS one · 2013Article
- Cancer microenvironment and cancer vaccine.Cancer microenvironment : official journal of the International Cancer Microenvironment Society · 2012Article
- Connective tissue growth factor in tumor pathogenesis.Fibrogenesis & tissue repair · 2012Article
- Therapeutic HPV DNA vaccines.Immunologic research · 2010Review
- Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis.Molecular therapy : the journal of the American Society of Gene Therapy · 2010Article
- Immunotherapy for cervical cancer: Research status and clinical potential.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2010Review
- An HDAC inhibitor enhances the antitumor activity of a CMV promoter-driven DNA vaccine.Cancer gene therapy · 2010Article
- DNA vaccines for cervical cancer.American journal of translational research · 2010Article
- Perspectives for preventive and therapeutic HPV vaccines.Journal of the Formosan Medical Association = Taiwan yi zhi · 2010Review
- Noncarrier naked antigen-specific DNA vaccine generates potent antigen-specific immunologic responses and antitumor effects.Gene therapy · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A novel method for generating an antigen-specific cancer vaccine and immunotherapy has emerged using a DNA vaccine. However, antigen-presenting cells (APCs) have a limited life span, which hinders their long-term ability to prime antigen-specific T cells. Connective tissue growth factor (CTGF) has a role in cell survival. This study explored the intradermal administration of DNA encoding CTGF with a model tumor antigen, human papilloma virus type 16 E7. Mice vaccinated with CTGF/E7 DNA exhibited a dramatic increase in E7-specific CD4(+) and CD8(+) T-cell precursors. They also showed an impressive antitumor effect against E7-expressing tumors compared with mice vaccinated with the wild-type E7 DNA. The delivery of DNA encoding CTGF and E7 or CTGF alone could prolong the survival of transduced dendritic cells (DCs) in vivo. In addition, CTGF/E7-transduced DCs could enhance a higher number of E7-specific CD8(+) T cells than E7-transduced DCs. By prolonging the survival of APCs, DNA vaccine encoding CTGF linked to a tumor antigen represents an innovative approach to enhance DNA vaccine potency and holds promise for cancer prophylaxis and immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.